BioLight’s New Investment in Sanoculis Ltd., a medical device company which develops an innovative surgical procedure for the ab-interno treatment of the Glaucoma

Tel Aviv (September 11, 2019) – BioLight is pleased to announce that today, it has signed a binding agreement, together with Mr. Zohar Zisapel, for its investment in Sanoculis Ltd. (the “Agreement” and “Sanoculis”). According to the Agreement, BioLight shall invest approx. USD 1.1M out of a total investment and …

Continue reading

Third stage of the binding agreement of investment in and acquisition in stages of IOPtima

Tel Aviv (July 1st, 2019) – Further to BioLight’s announcement dated November 21, 2017, regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima Ltd. (“IOPtima”or the “Company”) (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (the “Acquirer”), …

Continue reading

DiagnosTear Ltd. – CE Mark Approval

Tel Aviv (April 16, 2019) – BioLight is pleased to announce that today, its subsidiary DiagnosTear Ltd. (“DiagnosTear“)[1], announced receipt of CE Mark approval for its product that is based on the TeaRx ™ technology, which is used to diagnose, personalize treatment and monitor Dry eye syndrome by …

Continue reading

Micromedic sign a non-binding memorandum of understanding

BioLight (“the Company”) hereby announce that on March 25, 2019, according to the immediate report of Micromedic Technologies Ltd. (“Micromedic”), an investee company controlled by the Company, Micromedic entered into a non-binding memorandum of understanding with Nexstage Cannabis Innovation Ltd. (“Nexstage”, for information on Nexstage, see Section 6 of the …

Continue reading

Closing of the second stage of the binding agreement of investment in and acquisition in stages of IOPtima

Tel Aviv (September 27, 2018) – Further to BioLight’s announcement dated November 21, 2017, regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima Ltd. (“IOPtima”or the “Company”) (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (the “Acquirer”), …

Continue reading